Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 3:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Infertility
Interventions
Healing Touch, Desensitization Therapy
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Stanford, California
Conditions
The Rate of Kidney Transplants in Sensitized Patients.
Interventions
Not listed
Lead sponsor
BiologicTx, LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
2
States / cities
Seattle, Washington
Conditions
Sexual Dysfunction, Pelvic Floor Disorders, Gynecologic Cancer
Interventions
Integrated Physical Therapy and Coping Skills Training
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Completed Phase 2 Interventional Results available

Oral Immunotherapy for Childhood Egg Allergy

NCT00461097
Conditions
Hypersensitivity, Immediate Hypersensitivity, Food Hypersensitivity
Interventions
Egg oral immunotherapy, Control Group
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 18 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Conditions
Conversion Disorder, Psychogenic Movement Disorder, Functional Movement Disorder, Functional Neurological Disorder, Non-epileptic Seizures
Interventions
Embodied Virtual Reality Therapy, Virtual reality
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Stanford, California
Not listed Phase 1Phase 2 Interventional

Quantitating the Impact of Plerixafor

NCT02522572
Conditions
Transplants and Implants
Interventions
plerixafor, Bortezomib, plasmapheresis
Drug · Other
Lead sponsor
E. Steve Woodle
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Cincinnati, Ohio
Conditions
Tophaceous Gout
Interventions
Rituximab
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Chronic Kidney Disease (CKD)
Interventions
Vonsetamig
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 7 more
Completed Not applicable Interventional Results available

Integrated vs Sequential Treatment for PTSD and Addiction

NCT01211106
Conditions
PTSD, Substance Addiction
Interventions
Prolonged Exposure, Motivational Enhancement Therapy
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Minneapolis, Minnesota • Philadelphia, Pennsylvania
Completed Not applicable Interventional

Imaginal Exposure II Study: In-Vivo

NCT03934697
Conditions
Eating Disorder, Anorexia Nervosa, Bulimia Nervosa, Exposure
Interventions
imaginal exposure therapy
Behavioral
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Louisville, Kentucky
Completed Phase 2 Interventional Results available

OIT and Xolair® (Omalizumab) in Cow's Milk Allergy

NCT01157117
Conditions
Milk Allergy
Interventions
Placebo for omalizumab, Omalizumab, Milk powder
Biological · Drug
Lead sponsor
Hugh A Sampson, MD
Other
Eligibility
7 Years to 35 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Stanford, California • Baltimore, Maryland • New York, New York
Conditions
Peanut Hypersensitivity, Food Hypersensitivity, Food Allergy, Peanut Allergy
Interventions
Liquid peanut extract (Peanut SLIT)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Eating Disorders, Eating Disorders Symptoms
Interventions
Bilateral Stimulation
Behavioral
Lead sponsor
San Francisco State University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 1Phase 2 Interventional Results available

Tolerance Following Peanut Oral Immunotherapy

NCT01750879
Conditions
Peanut Allergy
Interventions
Peanut Flour, Oat Flour
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Specific Phobia
Interventions
D-cycloserine, Exposure therapy, Placebo
Drug · Behavioral
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hartford, Connecticut
Conditions
Kidney Failure, Chronic
Interventions
Obinutuzumab, Intravenous Immunoglobulin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 4 more
Active, not recruiting Phase 1Phase 2 Interventional

Carfilzomib and Belatacept for Desensitization

NCT05017545
Conditions
Highly Sensitized Prospective Kidney Transplant Recipients
Interventions
carfilzomib, belatacept, Bone marrow aspiration
Biological · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy

NCT02676765
Conditions
Immunologic Desensitization
Interventions
allergen extract tablet, Placebo tablet
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Posttraumatic Stress Disorder
Interventions
Virtual Reality Exposure Therapy
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Stress Disorders, Post-Traumatic
Interventions
Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR)
Other
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Social Anxiety Disorder (Social Phobia), Public Speaking Anxiety, Anhedonia, ANXIETY DISORDERS (or Anxiety and Phobic Neuroses), Phobic Disorders
Interventions
Positive Affect Treatment - Behavioral (PAT-B), Relaxation Treatment, Exposure Therapy
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Allergies, Allergic Rhinitis, Asthma
Interventions
sublingual immunotherapy, placebo sublingual immunotherapy
Drug
Lead sponsor
Stanford University
Other
Eligibility
5 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Stanford, California
Conditions
Anaphylaxis
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Peanut Allergy
Interventions
AR101 powder provided in capsules & sachets, Placebo powder provided in capsules & sachets
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
1 Year to 3 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Little Rock, Arkansas • Mountain View, California • Rolling Hills Estates, California + 11 more